Found 9 articles for: "biologics"
Treatment of Generalized Granuloma Annulare With Biologics and Oral JAK Inhibitors: A Case Series
February 2026 | Volume 25 | Issue 2 | Features | e26 | Copyright © February 2026
Two-Year Treatment Persistence of Guselkumab vs Other Biologics in Plaque Psoriasis Patients
August 2025 | Volume 24 | Issue 8 | Original Article | 762 | Copyright © August 2025
Objective: The study objective was to compare long-term treatment persistence between patients initiating guselkumab vs 3 commonly prescribed biologics in the United States.Read MoreThe Use of Biologic Therapeutic Regimens in Cutaneous and Systemic Mastocytosis: A Scoping Review
July 2025 | Volume 24 | Issue 7 | Original Article | 687 | Copyright © July 2025
Background: Mastocytoses, a category of diseases characterized by the clonal proliferation of mast cells and the release of their mediators, can be broadly classified as systemic...
Read MoreGuselkumab Efficacy by Psoriasis Disease Severity and Treatment History: VOYAGE 1 and 2 Post Hoc Analyses
February 2025 | Volume 24 | Issue 2 | Original Article | 196 | Copyright © February 2025
Background: The pivotal Phase 3 VOYAGE 1 and VOYAGE 2 studies established the robust efficacy and safety of guselkumab for up to 5 years in patients with moderate-to-severe psori...
Read MoreNew Biologics and Oral Drugs in Treatment of Moderate to Severe Psoriasis
August 2022 | Volume 21 | Issue 8 | Original Article | 826 | Copyright © August 2022
Psoriasis is known to have no definitive cure, which is in common with other inflammatory disorders. Various treatment options are available, and they help in decreasing the disease activity and impro...
Read MoreCOVID-19 Vaccine and Biologics: An Impending Dilemma
January 2021 | Volume 20 | Issue 1 | Editorials | 115 | Copyright © January 2021
The COVID-19 pandemic has forced healthcare providers across all specialties to adjust their methods of clinical practice. I...
Read MoreBiologics and Small Molecules in the Treatment of COVID-19
June 2020 | Volume 19 | Issue 6 | Features | 673 | Copyright © June 2020
Clinical and Molecular Effects of Interleukin-17 Pathway Blockade in Psoriasis
February 2020 | Volume 19 | Issue 2 | Original Article | 138 | Copyright © February 2020
The interleukin-17 (IL-17) pathway plays a crucial role in the development of psoriasis. Briefly, naive T cells differentiate into helper ...
Read MorePrescribing Patterns Associated With Biologic Therapies for Psoriasis from a United States Medical Records Database
August 2019 | Volume 18 | Issue 8 | Original Article | 745 | Copyright © August 2019
Introduction: Selecting a systemic therapy for patients with psoriasis is a complex process, based on a variety of factors including psoriasis severity, comorbid health conditions, ac...
Read More
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.